학술논문
Long-Term Immunological Memory of SARS-CoV-2 Is Present in Patients with Primary Antibody Deficiencies for up to a Year after Vaccination.
Document Type
Academic Journal
Author
Lucane Z; Riga Stradins University, Riga LV-1007, Latvia.; Slisere B; Riga Stradins University, Riga LV-1007, Latvia.; Pauls Stradins Clinical University Hospital, Riga LV-1007, Latvia.; Ozola L; Children's Clinical University Hospital, Riga LV-1007, Latvia.; Rots D; Riga Stradins University, Riga LV-1007, Latvia.; Children's Clinical University Hospital, Riga LV-1007, Latvia.; Papirte S; Riga Stradins University, Riga LV-1007, Latvia.; Vilne B; Riga Stradins University, Riga LV-1007, Latvia.; Gailite L; Riga Stradins University, Riga LV-1007, Latvia.; Kurjane N; Riga Stradins University, Riga LV-1007, Latvia.; Pauls Stradins Clinical University Hospital, Riga LV-1007, Latvia.; Children's Clinical University Hospital, Riga LV-1007, Latvia.
Source
Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2076-393X
Abstract
Some studies have found increased coronavirus disease-19 (COVID-19)-related morbidity and mortality in patients with primary antibody deficiencies. Immunization against COVID-19 may, therefore, be particularly important in these patients. However, the durability of the immune response remains unclear in such patients. In this study, we evaluated the cellular and humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in a cross-sectional study of 32 patients with primary antibody deficiency ( n = 17 with common variable immunodeficiency (CVID) and n = 15 with selective IgA deficiency) and 15 healthy controls. Serological and cellular responses were determined using enzyme-linked immunosorbent assay and interferon-gamma release assays. The subsets of B and T lymphocytes were measured using flow cytometry. Of the 32 patients, 28 had completed the vaccination regimen with a median time after vaccination of 173 days (IQR = 142): 27 patients showed a positive spike-peptide-specific antibody response, and 26 patients showed a positive spike-peptide-specific T-cell response. The median level of antibody response in CVID patients (5.47 ratio (IQR = 4.08)) was lower compared to healthy controls (9.43 ratio (IQR = 2.13)). No difference in anti-spike T-cell response was found between the groups. The results of this study indicate that markers of the sustained SARS-CoV-2 spike-specific immune response are detectable several months after vaccination in patients with primary antibody deficiencies comparable to controls.